DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in the HER2-Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including HER2-Negative Breast Cancer clinical trials and nonclinical stage products. It also covers the HER2-Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the HER2-Negative Breast Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, HER2-Negative Breast Cancer NDA approvals (if any), and product development activities comprising the technology, HER2-Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the HER2-Negative Breast Cancer Pipeline Report

 

• DelveInsight’s HER2-Negative Breast Cancer Pipeline report depicts a robust space with 85+ active players working to develop 85+ pipeline therapies for HER2-Negative Breast Cancer treatment.

 

• The leading HER2-Negative Breast Cancer Companies includes AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others

 

• Promising HER2 Negative Breast Cancer Pipeline Therapies includes BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38, Poziotinib Hydrochloride, EOC202, XZP-3287, RGT-419B, ASTX727, AND019, Lerociclib, SGN-STNV, SCR-6852, NMS-03305293, TOL2506, ZN-c5, AC682, HS-10342, ZEN003694, Nadunolimab, BLEX 404, Olinvacimab, AL101, eryaspase, EndoTAG-1, PMD-026, Chiauranib, OTS167PO, PVX-410, and others

 

• The HER2-Negative Breast Cancer companies and academics are working to assess challenges and seek opportunities that could influence HER2-Negative Breast Cancer R&D. The HER2-Negative Breast Cancer pipeline therapies under development are focused on novel approaches to treat/improve HER2-Negative Breast Cancer.

 

To explore more information on the latest breakthroughs in the HER2-Negative Breast Cancer Pipeline treatment landscape of the report, click here @ HER2-Negative Breast Cancer Pipeline Outlook

 

HER2-Negative Breast Cancer Overview

 

HER2-Negative Breast Cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and/or progesterone along with no expression of the human epidermal growth factor receptor 2 (HER2). Immunohistochemistry (IHC) test and/or Fluorescent in situ hybridization (FISH) is done to find out if cancer cells have estrogen and progesterone receptors. Common therapies for the treatment of HER2-Negative Breast Cancer include endocrine therapy (ET), ovarian suppression, aromatase inhibition, and/or CDK4/6 inhibitors.

 

Latest Developmental Activities in the HER2 Negative Breast Cancer Treatment Landscape

 

• In January 2022, Celcuity announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to the Company’s lead drug candidate, gedatolisib, for the treatment of patients with HR+/HER2- metastatic breast cancer after progression on CDK4/6 therapy.

 

• In December 2021, H3 Biomedicine Inc. (H3), announced the presentation of two posters at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held in a hybrid format on December 7- 10, 2021. The presentations include interim investigational data from H3’s ongoing clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.

 

• The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancers that progressed on prior endocrine and targeted therapies, according to results from the phase III EMERALD trial, which were presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.

 

• In November 2021, Olema Pharmaceuticals, Inc. announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development for the treatment of metastatic breast cancer and other women’s cancers.

 

For further information, refer to the detailed HER2-Negative Breast Cancer Unmet Needs, HER2-Negative Breast Cancer Market Drivers, and HER2-Negative Breast Cancer Market Barriers, click here for HER2-Negative Breast Cancer Ongoing Clinical Trial Analysis

 

HER2-Negative Breast Cancer Emerging Drugs Profile

 

• Capivasertib + Fulvestrant: AstraZeneca

Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently in phase III clinical studies for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.

 

• Dalpiciclib: Jiangsu HengRui Medicine

Dalpiciclib (formerly SHR 6390) is an orally administered small molecule and selective cyclin-dependent kinase (CDK)-4/6 inhibitor. Dalpiciclib in Combination with Letrozole or Anastrozole or Fulvestrant is in Phase III clinical evaluation in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.

 

HER2-Negative Breast Cancer Pipeline Therapeutics Assessment

There are approx. 85+ key companies which are developing the therapies for HER2-Negative Breast Cancer. The companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.

 

Request a sample and discover the recent advances in HER2-Negative Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ HER2-Negative Breast Cancer Treatment Landscape

 

Scope of the HER2-Negative Breast Cancer Pipeline Report

 

• Coverage- Global

 

• HER2 Negative Breast Cancer Companies- AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others

 

• HER2 Negative Breast Cancer Pipeline Therapies- BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38, Poziotinib Hydrochloride, EOC202, XZP-3287, RGT-419B, ASTX727, AND019, Lerociclib, SGN-STNV, SCR-6852, NMS-03305293, TOL2506, ZN-c5, AC682, HS-10342, ZEN003694, Nadunolimab, BLEX 404, Olinvacimab, AL101, eryaspase, EndoTAG-1, PMD-026, Chiauranib, OTS167PO, PVX-410, and others.

 

• HER2 Negative Breast Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for HER2-Negative Breast Cancer Market Drivers and HER2-Negative Breast Cancer Market Barriers, click here @ HER2-Negative Breast Cancer Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. HER2-Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-Negative Breast Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. HER2-Negative Breast Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Capivasertib + Fulvestrant: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II/III)
13. Inavolisib: Roche
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Afuresertib + Fulvestrant: Laekna
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. HER2-Negative Breast Cancer Key Companies
23. HER2-Negative Breast Cancer Key Products
24. HER2-Negative Breast Cancer- Unmet Needs
25. HER2-Negative Breast Cancer- Market Drivers and Barriers
26. HER2-Negative Breast Cancer- Future Perspectives and Conclusion
27. HER2-Negative Breast Cancer Analyst Views
28. HER2-Negative Breast Cancer Key Companies
29. Appendix

 

Got Queries? Find out the related information on HER2-Negative Breast Cancer Mergers and acquisitions, HER2-Negative Breast Cancer Licensing Activities @ HER2-Negative Breast Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/